Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
OSD
Sort By
Newest First
1 / 3
1 / 3
Minitablets
Minitablets: Enhancing Safety and Palatability for Pediatric Medicines
Gus LaBella
Mikart
PAO-09-24-CL-01
Aug 30, 2024
Developability
Assessing Developability and Designing Advanceable Formulations from the Start
Nazar Elkarim, Ph.D.
Mikart
PAO-09-24-CL-02
Aug 26, 2024
Advanceability
Right from the Start: Designing Advanceable Formulations and Processes at Phase I
Serán Bioscience
PAO-02-24-CL-09
Feb 26, 2024
CDMO
Maximizing Outsourcing Benefits for Virtual Pharma Companies
William Kazimier
Tedor Pharma Services
PAO-09-23-CL-08
Jan 11, 2024
Formulation
Addressing Swallowing and Palatability Issues with Patient-Friendly Dosage Forms
Gus LaBella
Mikart
PAO-09-23-CL-04
Oct 03, 2023
OSD and Liquid
Reshoring Manufacturing and Targeted, Specialty Medicines
Mikart
PAO-05-22-R250-05
May 17, 2022
Advanced Excipients
How the Developability Classification System and Advanced Excipients Enable the Formulation of Poorly Soluble APIs
Daniel Joseph Price, Ph.D.
MilliporeSigma
PAO-04-022-CL-07
Apr 27, 2022
Streamlining OSD Operations from Tableting through Serialization
Richard Walkup
Avara Pharmaceutical Services
PA789
Oct 21, 2021
Tablet Coating
An Easy-to-Use Tablet Coating Polymer to Increase Coating Process Efficiency and Flexibility
Thomas Kipping, Ph.D.
MilliporeSigma
PAO-09-21-CL-06
Sep 14, 2021
Solving the Patient-Centric Formulation Riddle
Beau Garrett
Tapemark
PA806
Sep 09, 2021
Orally Disintegrating Tablets
A Revolutionary Excipient Platform for Super-Fast Disintegrating ODTs
Bill McCarthy; Geetha Thanga Mariappan, Ph.D.
SPI Pharma
PAO-07-21-CL-03
Jul 13, 2021
Launch
SPI Pharma Launches UltraBurst™, the First In Class Preformulated Platform for Flash Orally Dispersible Tablets
SPI Pharma
PR-M07-21-03
Jul 12, 2021
OSD Technology
Patient-Centric Innovations in OSD
BDD Pharma
PAO-04-22-R221-11
Apr 09, 2021
Specialized OSD Services
Avara Pharmaceutical Services: Specialization with a Client-Centric Approach
Deborah A. Graham
Avara Pharmaceutical Services
PAP-Q4-20-CL-003
Dec 09, 2020
The Future of Healthcare
How Does Avara Pharmaceutical Services Envision the Future of the Pharma/Biopharma Industry?
Avara Pharmaceutical Services
PAP-Q4-20-RT2-011
Dec 09, 2020
Nice Insight Overview
The Benefits of Expanding OSD Capacity
Nigel Walker
Nice Insight
PAP-Q3-20-NI-001
Sep 29, 2020
The Future of Healthcare
How Is Avara Pharmaceutical Services Evolving its Business Model to Meet the Future of Healthcare?
Avara Pharmaceutical Services
PAP-Q3-20-RT2-003
Sep 29, 2020
Over-the-Counter Conversions
Avara Pharmaceutical Services: Achieving Successful OSD Rx-to-OTC Conversions
Patrick Hatem
Avara Pharmaceutical Services
PAP-Q3-20-CL-007
Sep 29, 2020
The Future of Healthcare
How is Avara Innovating through the Pandemic and Beyond to Define the Future of Healthcare?
Avara Pharmaceutical Services
PAP-Q2-20-RT2-010
Jul 01, 2020
M&A
Piramal Pharma Solutions Announces Acquisition of Solid Oral Dosage Drug Product Facility in Sellersville, Pennsylvania from G&W Laboratories Inc.
Piramal Pharma Solutions
PR-M06-20-NI-033
Jun 25, 2020
